Prices delayed by at least 15 minutes | Print
Adverum Biotechnologies (ADVM)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Address
800 Saginaw Drive
Redwood CIty
CA
USA
94063
Telephone
+1 650 6569323
Forecast key dates
Name | Key Date |
---|---|
Adverum Biotechnologies Inc First Quarter Earnings Results for 2025 | 2025-05-09T00:00:00 |
Adverum Biotechnologies Inc Annual Report for 2024 | 2025-05-02T00:00:00 |
Adverum Biotechnologies Inc Fourth Quarter Earnings Results for 2024 | 2025-03-18T00:00:00 |
Adverum Biotechnologies Inc Third Quarter Earnings Results for 2024 | 2024-11-08T00:00:00 |
Adverum Biotechnologies Inc Second Quarter Earnings Results for 2024 | 2024-08-09T00:00:00 |
Adverum Biotechnologies Inc Annual General Meeting for 2024 | 2024-06-07T08:00:00 |
H.C. Wainwright 2nd Annual BioConnect Investor Conference | 2024-05-20T23:00:00 |
BofA Securities 2024 Health Care Conference | 2024-05-16T15:40:00 |
2024 RBC Global Healthcare Conference | 2024-05-14T16:05:00 |
Adverum Biotechnologies Inc First Quarter Earnings Results for 2024 | 2024-05-09T00:00:00 |
Adverum Biotechnologies Inc Annual Report for 2023 | 2024-05-02T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.